Navigation Links
CareFusion Reports First Quarter Fiscal 2012 Results
Date:11/7/2011

nrecurring(in millions)GAAP(4)Items(2)Adjusted(3)Medical SystemsRevenue$

468

$

-

$

468Operating Income $

68

$

22

$

90Procedural SolutionsRevenue$

343

$

-

$

343Operating Income $

11

$

17

$

28____________1Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring charges.  2Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.  Certain nonrecurring costs previously reported were applicable to the International Surgical Products (ISP) business and therefore were reclassified to be reflected as part of that business.3Adjusted financial information reflects GAAP results adjusted on a non-GAAP basis to exclude nonrecurring items noted.4Previously reported GAAP amounts have been adjusted to reflect the impact of the divestiture of the ISP business, and re-segmentation of the Company's businesses into two new reportable segments.  The ISP business was divested in April 2011, and has been classified as discontinued operations. CAREFUSION CORPORATIONSEGMENT AND SELECT BUSINESS LINE REVENUES(UNAUDITED)Quarter Ended September 30,(in millions) 20112010(1)Percent
ChangeMedical SystemsDispensing Technologies

$

237

$

205

16

%Infusion Systems206192

7Respiratory Technologies6065

(8)Other66

-Total Medical Systems

$

509

$

468

9Procedural SolutionsInfection Prevention

$

138

$

135

2

%Medical Specialties7878

-Specialty Disposables6670

(6)Other5360

(12)Total Procedural Solutions

$

335

$

343

(2)Total CareFusion$

844

$

811

4

%____________1Previously rep
'/>"/>

SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
2. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
3. InterMune Reports Third Quarter 2011 Financial Results and Business Highlights
4. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
6. Caliper Life Sciences Reports Third Quarter 2011 Results
7. Neurocrine Biosciences Reports Third Quarter 2011 Results
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... PA (PRWEB) September 02, 2014 ... a new highly efficient, cost effective approach to ... Patent No. 8,820,265 by the U.S. Patent and ... to Opertech. , “Opertech’s taste evaluation ... the first automated high throughput system for rapid ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014  Xencor, ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today announced the appointment of ... development and the appointment of Lloyd Rowland ... general counsel. "Debra,s expertise in ...
(Date:9/2/2014)... , Sept. 2, 2014  Synthetic Biologics, Inc. ... biologic and drug candidates targeting specific pathogens that ... results from its final preclinical toxicology study of ... guidance, this bridging study was required to move ... to prevent the devastating effects of Clostridium ...
(Date:9/2/2014)... Mount, NC (PRWEB) September 02, 2014 ... establishment of its 11th clinical research site: PMG Research ... assumed ownership and operation of the clinical research department ... further expanding PMG’s presence in eastern North Carolina. This ... patients. For the patients in Rocky Mount and the ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3
... German . , They have been used as ... they are making rapid inroads in high performance applications: CMOS ... and digital cameras. The automotive industry, for instance, has discovered ... them in driver assistance systems from parking aids and ...
... Palatin Technologies, Inc. (NYSE Amex: PTN ) today announced ... of its common stock and warrants to purchase common stock in ... and there can be no assurance as to whether or when ... or terms of the offering. Roth Capital Partners is ...
... 23, 2011 Scarguard Labs, LLC, a closely held ... other dermatological problems through the use of multi-technology drugs ... that they have received approval from Health Canada to ... "We are very pleased to gain approval for ...
Cached Biology Technology:UV-transparent coating for image sensors 2Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants 2Palatin Technologies, Inc. Announces Proposed Public Offering of Common Stock and Warrants 3
(Date:9/2/2014)... through a U.S. suburb , Observations and mapping ... the hours and days after the August 24 earthquake ... earthquake caused so much damage in the region, according ... by the American Geophysical Union. , ... Places to Direct Our Curiosity , Selecting where ...
(Date:9/2/2014)... Human Genetics (ASHG) and the National Human Genome ... of Health, have named Katherine D. Blizinsky, PhD, ... newest ASHG/NHGRI Genetics and Public Policy Fellow. The ... Public Policy Fellowship is intended to help early-career ... research policy at a national level. Fellows in ...
(Date:9/2/2014)... team of University of Maryland physicists has published ... say make possible new nanostructures and nanotechnologies with ... quantum computing advances to new sensor development. , ... Nature Communications the Maryland scientists, primary discovery ... nanostructures that uses a connector, or "intermedium," nanoparticle ...
Breaking Biology News(10 mins):This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2ASHG and NHGRI award genetics and public policy fellowship 2New synthesis method may shape future of nanostructures, clean energy 2New synthesis method may shape future of nanostructures, clean energy 3
... June, 2010) SAGE, the world,s fifth leading independent ... the Bulletin of the Atomic Scientists from September ... other experts who had created the atomic bomb as part ... threats to the survival and development of humanity from nuclear ...
... research led by the University of Leicester and published in ... first time the mechanism by which memories are formed. ... found one of the key proteins involved in the process ... to impact drug design to treat Alzheimer,s disease. The ...
... the hon-shimeji mushroom is a delicacy costing up to SEK 8,000 ... of Gothenburg, Sweden, has discovered that this tasty fungus also grows ... of interest in Sweden, and definitely in Japan once these discoveries ... Lyophyllum is a family of many different species ...
Cached Biology News:SAGE to publish the Bulletin of the Atomic Scientists 2Memories are made of this 2Japanese gourmet mushroom found in Sweden 2Japanese gourmet mushroom found in Sweden 3
11-keto Testosterone EIA Antiserum hormones steroids antisera antiserum eias enzyme immunoassays reagents 11-keto-testosterone...
... (phospho S207) ( Abpromise for ... Antigen: Synthetic phosphopeptide derived from ... of Serine 207 (V-D-S P -V-A). ... 5608 Swiss ...
Anti-human L-Ficolin, Clone GN4, Monoclonal Antibody...
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: